Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 25 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Antimalarials; Attenuated vaccines; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 25 May 2017 Sanaria and University Hospital Tuebingen plan the phase I MALACHITE trial for Falciparum malaria (Prevention, Combination therapy) in Germany (IV) (NCT02858817)
  • 01 May 2017 Phase-I clinical trials in Falciparum malaria (In volunteers, Prevention) in Netherlands (IV) (NCT03163121)
  • 23 Mar 2017 National Institutes of Health Clinical Center plans a phase I trial for Malaria (Prevention) in USA (NCT03083847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top